Tango Therapeutics (NASDAQ:TNGX) Stock Price Down 8.7% – Here’s What Happened

Posted by Francis Steltz on Jul 13th, 2026

Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX – Get Free Report) dropped 8.7% on Monday . The stock traded as low as $28.33 and last traded at $28.3490. Approximately 1,561,403 shares were traded during trading, a decline of 58% from the average session volume of 3,745,211 shares. The stock had previously closed at $31.06.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. Wolfe Research set a $35.00 price target on shares of Tango Therapeutics and gave the company an “outperform” rating in a research note on Monday, June 8th. B. Riley Financial restated a “buy” rating on shares of Tango Therapeutics in a research report on Monday, June 8th. Mizuho set a $36.00 target price on shares of Tango Therapeutics in a report on Monday, June 8th. Canaccord Genuity Group increased their target price on shares of Tango Therapeutics from $42.00 to $46.00 and gave the company a “buy” rating in a research report on Monday, June 29th. Finally, Jefferies Financial Group raised shares of Tango Therapeutics from a “hold” rating to a “buy” rating and boosted their price target for the company from $27.00 to $60.00 in a research report on Thursday, June 25th. Twelve analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $41.50.

Get Our Latest Stock Analysis on Tango Therapeutics

Tango Therapeutics Trading Down 8.3%

The business has a 50 day moving average of $26.09 and a 200-day moving average of $19.32. The stock has a market cap of $4.12 billion, a PE ratio of -34.47 and a beta of 1.12.

Tango Therapeutics (NASDAQ:TNGX – Get Free Report) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($0.32) earnings per share for the quarter, meeting the consensus estimate of ($0.32). Research analysts expect that Tango Therapeutics, Inc. will post -1.28 EPS for the current fiscal year.

Insider Transactions at Tango Therapeutics

In other Tango Therapeutics news, insider Adam Crystal sold 38,460 shares of Tango Therapeutics stock in a transaction on Wednesday, April 15th. The shares were sold at an average price of $25.00, for a total value of $961,500.00. Following the transaction, the insider directly owned 112,622 shares in the company, valued at approximately $2,815,550. The trade was a 25.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Over the last quarter, insiders have sold 119,460 shares of company stock worth $2,951,130. Company insiders own 6.50% of the company’s stock.

Hedge Funds Weigh In On Tango Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Global Retirement Partners LLC purchased a new stake in Tango Therapeutics during the 4th quarter valued at approximately $35,000. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Tango Therapeutics by 148,800.0% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,467 shares of the company’s stock valued at $40,000 after purchasing an additional 4,464 shares during the last quarter. ANTIPODES PARTNERS Ltd acquired a new position in shares of Tango Therapeutics in the fourth quarter valued at approximately $40,000. State of Wyoming acquired a new position in shares of Tango Therapeutics in the first quarter valued at approximately $128,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Tango Therapeutics by 52.2% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,544 shares of the company’s stock worth $58,000 after purchasing an additional 2,243 shares during the last quarter. Hedge funds and other institutional investors own 78.99% of the company’s stock.

About Tango Therapeutics

(Get Free Report)

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company’s lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.